SKYGLO: Glofitamab in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma
Condition: Diffuse Large B-Cell Lymphoma
Sponsor: Hoffmann-La Roche
Full Title
Protocol GO44145: A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and
Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab,
Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously
Untreated Patients with Large B-Cell Lymphoma
Study Treatment
CD20xCD3 bispecific antibody glofitamab in combination with Pola-R-CHP vs Pola-R-CHP alone
Eligibility/Info
Untreated CD20-positive Large B-Cell Lymphoma of one of the following types:
- DLBCL, not otherwise specified (NOS) including germinal centre B-cell type, activated B-cell type
- T-cell/histiocyte-rich large B-cell lymphoma
- Epstein-Barr virus-positive DLBCL, NOS
- Kaposi’s sarcoma-associated herpesvirus/human herpesvirus-8 positive DLBCL
- DLBCL/HGBCL with MYC and BCL2 rearrangements
- HGBCL, NOS
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
